Accelerating drug discovery through chemical proteomics
Generate biologically relevant target-engagement data before costly downstream decisions
Most drug discovery decisions are still based on data generated outside biological reality.
Omivera helps biotech and pharmaceutical companies make better small-molecule development decisions through chemical proteomics.
Generate target engagement, selectivity, and mechanism-of-action insights before costly downstream studies.
We help you
see more
By the time a compound reaches lead optimization, uncertainty becomes expensive. Traditional assays provide part of the picture.
You need to know:
Is my compound engaging its target?
Are there unexpected off-target effects?
Is the mechanism of action clear?
Is evidence strong enough to proceed?
At Omivera, we use chemical proteomics to help you understand how compounds interact with proteins in biologically relevant systems.
Rather than relying solely on artificial assay conditions, you gain insight into target engagement, selectivity, protein activity, and mechanism of action in a setting that better reflects biological reality. The result is stronger evidence to support critical development decisions during lead optimization and preclinical development.
1. Hit identification
You are exploring early kinase inhibitor candidates and need a first view of cellular target engagement.
2. Lead Optimization
You are selecting lead candidates and need confidence in selectivity, mechanism, and off-target behavior.
3. Preclinical Development
You are preparing for in vivo studies and need biologically relevant data before major downstream investment
4. Translational & In Vivo Studies
You are evaluating compound behavior in more complex biological systems and translational models.
Many critical drug-target interactions cannot be fully understood through biochemical assays alone.
Chemical proteomics enables direct measurement of compound behaviour in biologically relevant systems, helping you move forward with greater confidence.
→ Understand target engagement
→ Assess selectivity
→ Identify off-target interactions
→ Investigate mechanism of action
→ Support candidate prioritization
Every development
challenge requires a
different perspective.
Our platform portfolio helps you answer a wide range of drug discovery questions through biologically relevant protein-level insights.
CellEKT
Measure target engagement across the kinome in biologically relevant systems. CellEKT is Omivera’s proprietary platform for measuring target engagement across the kinome using chemical proteomics..
Activity-Based Protein Profiling (ABPP)
Characterize active enzyme populations and understand how compounds influence protein activity.
Residue-Specific Proteomics
Investigate compound interactions at the amino acid level.
Probe-Enabled Workflows
Tailored chemical proteomics studies designed around your scientific question.
Ensure every development decision is guided by biology that actually matters.
Joel Rüegger, CEO
CellEKT Reaches 100,000th Cell Processing Run
The milestone highlights growing adoption of automated workflows as cell therapy developers seek greater consistency and scalability.
Omivera Launches Strategic Partnership Program to Support Emerging Biotech Companies
A new initiative designed to help biotech startups accelerate growth through expert guidance, strategic support, and industry connections.
Omivera Expands European Operations with New Innovation Hub in Leiden
The new facility strengthens Omivera’s presence in Europe’s life sciences ecosystem and creates new opportunities for research collaboration and innovation.